Wei Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wei Zhang has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Chengyu Xiao
2 shared publications- Hongbo Wang
Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan China
2 shared publications - Lu Xu
School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China
2 shared publications - Rong Zhao2 shared publications
Shuqi Chi
2 shared publications- Xianbin Zhang
Department of General Surgery and Institute of Precision Diagnosis and Treatment of Digestive System Tumors, Carson International Cancer Center, Shenzhen University General Hospital, Shenzhen University, Shenzhen, China
2 shared publications
Latest Publications
- 18 October 2023
- Published by Elsevier in Environmental Research
- Vol. 240 (Pt 2) , 117443
Acquired and intrinsic gemcitabine resistance in pancreatic cancer therapy: Environmental factors, molecular profile and drug/nanotherapeutic approaches
- 18 October 2023
- Published by Elsevier in Environmental Research
- Vol. 240 (Pt 2) , 117443
Acquired and intrinsic gemcitabine resistance in pancreatic cancer therapy: Environmental factors, molecular profile and drug/nanotherapeutic approaches
- 31 August 2023
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 11 (20) , 6894-6905
Functionalized nanohybrids with rod shape for improved chemo-phototherapeutic effect against cancer by sequentially generating singlet oxygen and carbon dioxide bubbles
The application of hybrid nanocarriers is expected to play an active role in improving treatment of chemotherapy and phototherapy. Herein, a nanohybrid with a core of mesoporous silica nanorods and shell of folate-functionalized zeolite imidazole framework (ZIF-8/FA) was synthesized via polydopamine (PDA)-mediated integration. A chemotherapeutic drug (DOX), bubble generator (NH4HCO3, ABC), and photosensitive agent (ICG) were simultaneously loaded into the delivery system to construct smart ZIF-8/FA-coated mesoporous silica nanorods (IDa-PRMSs@ZF). We found that ICG endowed the designed delivery system with a moderate photothermal conversion efficiency of 26.06% and the capacity to release 1O2. The produced hyperthermia caused ABC to decompose and further generate carbon dioxide bubbles, thereby facilitating DOX release, sequentially. Importantly, the underlying mechanism was also investigated using mathematical kinetic modeling. The tumor inhibition rate of IDa-PRMSs@ZF under NIR irradiation reached 83.8%. This study provides a promising strategy based on rod-shaped nanohybrids for effective combination antitumor therapy.
- 31 August 2023
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 11 (20) , 6894-6905
Functionalized nanohybrids with rod shape for improved chemo-phototherapeutic effect against cancer by sequentially generating singlet oxygen and carbon dioxide bubbles
The application of hybrid nanocarriers is expected to play an active role in improving treatment of chemotherapy and phototherapy. Herein, a nanohybrid with a core of mesoporous silica nanorods and shell of folate-functionalized zeolite imidazole framework (ZIF-8/FA) was synthesized via polydopamine (PDA)-mediated integration. A chemotherapeutic drug (DOX), bubble generator (NH4HCO3, ABC), and photosensitive agent (ICG) were simultaneously loaded into the delivery system to construct smart ZIF-8/FA-coated mesoporous silica nanorods (IDa-PRMSs@ZF). We found that ICG endowed the designed delivery system with a moderate photothermal conversion efficiency of 26.06% and the capacity to release 1O2. The produced hyperthermia caused ABC to decompose and further generate carbon dioxide bubbles, thereby facilitating DOX release, sequentially. Importantly, the underlying mechanism was also investigated using mathematical kinetic modeling. The tumor inhibition rate of IDa-PRMSs@ZF under NIR irradiation reached 83.8%. This study provides a promising strategy based on rod-shaped nanohybrids for effective combination antitumor therapy.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from UBE2C Is Upregulated by Estrogen and Promotes Epithelial–Mesenchymal Transition via p53 in Endometrial Cancer
This file shows supplementary materials and methods
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from UBE2C Is Upregulated by Estrogen and Promotes Epithelial–Mesenchymal Transition via p53 in Endometrial Cancer
This file shows supplementary materials and methods
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from UBE2C Is Upregulated by Estrogen and Promotes Epithelial–Mesenchymal Transition via p53 in Endometrial Cancer
This file shows supplementary materials and methods
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from UBE2C Is Upregulated by Estrogen and Promotes Epithelial–Mesenchymal Transition via p53 in Endometrial Cancer
This file shows supplementary materials and methods
- 1 April 2022
- Published by American Scientific Publishers in Journal of Biomaterials and Tissue Engineering
- Vol. 12 (4) , 690-694
Facile Preparation of Paclitaxel Nano-Suspensions to Treat Lung Cancer
Lung cancer is a worldwide issue which account for the death of thousands every year. Paclitaxel (PTX) as the first line chemotherapy drug to treat lung cancer, its clinical applications is largely limited by its poor solubility. The facile preparation of pharmaceutical formulations to increase the solubility as well as targetability of PTX is of vital importance in lung cancer treatment. Herein, we introduced a facile method to prepare PTX nano-suspensions (NSs), which have high drug loading as well as well-dispersed particle size. The in vitro cell experiments revealed its capability to enhance the drug accumulation in A549 cells than free PTX. Moreover, in vivo animal assay suggested its better tumor accumulation and antitumor efficacy than PTX injection (Taxol).
- 1 April 2022
- Published by American Scientific Publishers in Journal of Biomaterials and Tissue Engineering
- Vol. 12 (4) , 690-694
Facile Preparation of Paclitaxel Nano-Suspensions to Treat Lung Cancer
Lung cancer is a worldwide issue which account for the death of thousands every year. Paclitaxel (PTX) as the first line chemotherapy drug to treat lung cancer, its clinical applications is largely limited by its poor solubility. The facile preparation of pharmaceutical formulations to increase the solubility as well as targetability of PTX is of vital importance in lung cancer treatment. Herein, we introduced a facile method to prepare PTX nano-suspensions (NSs), which have high drug loading as well as well-dispersed particle size. The in vitro cell experiments revealed its capability to enhance the drug accumulation in A549 cells than free PTX. Moreover, in vivo animal assay suggested its better tumor accumulation and antitumor efficacy than PTX injection (Taxol).
- 1 January 2022
- Published by Elsevier in Microporous and Mesoporous Materials
- Vol. 330, 111634
Alanine modified chiral-responsive mesoporous silica as nanocarriers for improved oral bioavailability of carvedilol
- 1 January 2022
- Published by Elsevier in Microporous and Mesoporous Materials
- Vol. 330, 111634
Alanine modified chiral-responsive mesoporous silica as nanocarriers for improved oral bioavailability of carvedilol